Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Inventory (2016 - 2025)

Historic Inventory for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to $11.9 million.

  • Ligand Pharmaceuticals' Inventory fell 2891.28% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 2891.28%. This contributed to the annual value of $14.1 million for FY2024, which is 4111.56% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Inventory stood at $11.9 million, which was down 2891.28% from $15.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Inventory high stood at $39.9 million for Q2 2021, and its period low was $11.9 million during Q3 2025.
  • Its 5-year average for Inventory is $22.4 million, with a median of $22.3 million in 2022.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 97903.84% in 2021, then crashed by 5135.04% in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Inventory stood at $27.3 million in 2021, then plummeted by 51.35% to $13.3 million in 2022, then surged by 80.3% to $24.0 million in 2023, then crashed by 41.12% to $14.1 million in 2024, then dropped by 15.69% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $15.5 million for Q2 2025, and $14.6 million during Q1 2025.